Register Now

Citi expects 17% upside in Cipla shares but warns on delay in Abraxane launch

Citi’s commentary comes as China-based pharma company Jiangsu Hengrui has received approval for Paclitaxel, the generic version of BMS’ Abraxane.

Leave a Reply

Your email address will not be published. Required fields are marked *